Episode 21: Antibiotic Resistance: How CARB-X Helps New Companies Get a Running Start

Kevin Outterson, the Executive Director of Boston-based CARB-X, a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria, joins the podcast to talk with Gunnar about the early-stage landscape for biotechnology companies developing novel antibiotics. Unlike the AMR ActionFund, CARB-X doesn't take equity positions in new companies, but rather provides grants and infrastructure support for companies moving through the drug development process. Gunnar and Kevin also talk about the PASTEUR and DISARM Acts as potential legislative fixes for the antibiotic marketplace. Kevin also points to an assumption that has long been made about generic drugs, which falls short for antibiotics and leaves them in a place that leaves them vulnerable to present market conditions. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policyLearn more about your ad choices. Visit https://podcastchoices.com/adchoices